JG
ALNY icon

Jefferies Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jefferies Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$9.35M Buy
46,726
+29,831
+177% +$5.69M 0.08% 202
2022
Q2 		$2.46M Sell
16,895
-2,893
-15% -$410K 0.02% 541
2022
Q1 		$3.23M Sell
19,788
-12,171
-38% -$1.85M 0.02% 521
2021
Q4 		$5.42M Buy
31,959
+18,515
+138% +$3.44M 0.03% 434
2021
Q3 		$2.54M Sell
13,444
-3,096
-19% -$581K 0.02% 680
2021
Q2 		$2.8M Buy
+16,540
New +$2.42M 0.02% 637
2021
Q1 		– Sell
-18,704
Closed -$2.81M – 1590
2020
Q4 		$2.43M Buy
18,704
+5,186
+38% +$692K 0.02% 647
2020
Q3 		$1.97M Sell
13,518
-26
-0.2% -$3.69K 0.02% 576
2020
Q2 		$2.01K Sell
13,544
-3,460
-20% -$466K 0.02% 551
2020
Q1 		$1.85M Buy
17,004
+5,184
+44% +$598K 0.02% 723
2019
Q4 		$1.36M Buy
11,820
+8,607
+268% +$858K 0.01% 1279
2019
Q3 		$258K Buy
+3,213
New +$254K ﹤0.01% 2251
2018
Q4 		– Sell
-31,102
Closed -$2.72M – 2129
2018
Q3 		$2.72M Buy
31,102
+30,702
+7,676% +$3.09M 0.02% 836
2018
Q2 		$39K Sell
400
-25,995
-98% -$2.58M ﹤0.01% 2210
2018
Q1 		$3.14M Buy
26,395
+11,895
+82% +$1.53M 0.02% 662
2017
Q4 		$1.84M Buy
14,500
+2,000
+16% +$251K 0.01% 1033
2017
Q3 		$1.47M Buy
+12,500
New +$1.07M 0.01% 1094
2016
Q2 		– Sell
-1,700
Closed -$107K – 2110
2016
Q1 		$107K Sell
1,700
-11,514
-87% -$766K ﹤0.01% 1961
2015
Q4 		$1.24M Buy
13,214
+918
+7% +$85.1K 0.01% 1081
2015
Q3 		$988K Sell
12,296
-65,100
-84% -$7.23M 0.01% 1213
2015
Q2 		$9.28M Buy
77,396
+15,072
+24% +$1.8M 0.05% 316
2015
Q1 		$6.51M Buy
+62,324
New +$6.32M 0.04% 343
2014
Q2 		– Sell
-1,053
Closed -$71K – 2044
2014
Q1 		$71K Buy
+1,053
New +$81.5K ﹤0.01% 1862
2013
Q3 		– Sell
-60,079
Closed -$1.86M – 1911
2013
Q2 		$1.86M Buy
+60,079
New +$1.6M 0.02% 539

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jefferies Group's ALNY Position: Q3 2022 in Review

Jefferies Group increased its Alnylam Pharmaceuticals (ALNY) stake by 177% in Q3 2022, buying an estimated $5.69M and bringing the position to 46,726 shares worth $9.35M. The position accounts for 0.08% of the portfolio, ranked #202.

Jefferies Group first reported a position in ALNY in Q2 2013 and has held it in 24 quarters since. 496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Jefferies Group held 46,726 shares of Alnylam Pharmaceuticals worth $9.35M as of Q3 2022.
  • Jefferies Group bought 29,831 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $5.69M.
  • Alnylam Pharmaceuticals made up 0.08% of Jefferies Group's portfolio in Q3 2022, its #202 holding.
  • Jefferies Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • 496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.